effects of glp-1 receptor agonists on neurological complications of diabetes Pleitropic or GLP-1R (Adapted from references... Clinical Focus on GLP-1 Agonists

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

Currently used antidepressant drugs, which mostly target brain monoaminergic neurotransmission, have limited clinical efficacy

Week 2+: Regular daily movements, burps gone, sustained energy and mental clarity

Introduction The global obesity market is entering a new phase

Its pathogenesis is unknown

In a phase 2 study, amycretin showed a mean weight reduction of up to 24.3%, which is comparable to or even greater than the weight loss seen with tirzepatide and similar to the results for retatrutide